New Drug Review

Possible P&T Committee Decisions

(May 2015)

1. New drug, no other drugs for indication.
   a. Take no action
   b. Limit to approved indication

2. New drug, other drugs previously approved for indication. Class is not currently managed.
   a. Take no action
   b. Limit to approved indication
   c. Efficacy or safety concerns? Require trial and failure of existing drugs or require a hard prior authorization.
   d. Cost concerns? Make recommendation based on efficacy and safety and request that the Department of Health make final decision based on cost net rebate.
   e. Add entire class to the Preferred Drug List
   f. Do other drugs in the class need similar PA criteria? For instance, should they all be limited to indication?

3. New drug, current PDL class.
   a. Recommendation regarding comparative safety and efficacy of new drug vs. existing drugs in class. If available evidence suggests no difference between new drug and existing drugs, Department of Health will make final decision regarding PDL placement after cost analysis. If there is clear superiority in safety or efficacy to all other agents in the class, cost will not be a factor.